GeneReach Biotechnology (4171) - Total Liabilities

Latest as of December 2025: NT$284.34 Million TWD ≈ $8.96 Million USD

Based on the latest financial reports, GeneReach Biotechnology (4171) has total liabilities worth NT$284.34 Million TWD (≈ $8.96 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore GeneReach Biotechnology (4171) cash conversion ratio to assess how effectively this company generates cash.

GeneReach Biotechnology - Total Liabilities Trend (2017–2025)

This chart illustrates how GeneReach Biotechnology's total liabilities have evolved over time, based on quarterly financial data. Check GeneReach Biotechnology (4171) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

GeneReach Biotechnology Competitors by Total Liabilities

The table below lists competitors of GeneReach Biotechnology ranked by their total liabilities.

Company	Country	Total Liabilities
Success Transformer Corporation Bhd KLSE:7207	Malaysia	RM72.80 Million
Green Impact Partners Inc V:GIP	Canada	CA$73.28 Million
Angus Ventures Inc V:GUS	Canada	CA$1.77 Million
TRC Synergy Bhd KLSE:5054	Malaysia	RM354.30 Million
AtlasClear Holdings, Inc. NYSE MKT:ATCH	USA	$55.94 Million
G11 Resources Ltd AU:G11	Australia	AU$161.95K
WPP PLC LSE:WPP	UK	GBX19.99 Billion
US Energy Corp NASDAQ:USEG	USA	$21.46 Million

Liability Composition Analysis (2017–2025)

This chart breaks down GeneReach Biotechnology's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4171 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.41	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.48	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.32	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how GeneReach Biotechnology's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for GeneReach Biotechnology (2017–2025)

The table below shows the annual total liabilities of GeneReach Biotechnology from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$284.34 Million ≈ $8.96 Million	-16.62%
2024-12-31	NT$341.00 Million ≈ $10.74 Million	+8.70%
2023-12-31	NT$313.71 Million ≈ $9.88 Million	-39.58%
2022-12-31	NT$519.23 Million ≈ $16.36 Million	-12.93%
2021-12-31	NT$596.35 Million ≈ $18.79 Million	+55.81%
2020-12-31	NT$382.75 Million ≈ $12.06 Million	+128.07%
2019-12-31	NT$167.82 Million ≈ $5.29 Million	-56.15%
2018-12-31	NT$382.68 Million ≈ $12.06 Million	+8.65%
2017-12-31	NT$352.21 Million ≈ $11.10 Million	--

About GeneReach Biotechnology

TWO:4171 Taiwan Biotechnology

Market Cap

$34.90 Million

NT$1.11 Billion TWD

Market Cap Rank

#23193 Global

#1461 in Taiwan

Share Price

NT$19.20

Change (1 day)

-0.52%

52-Week Range

NT$16.95 - NT$27.00

All Time High

NT$246.40